Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Evolus reports robust Q4 earnings, eyes international expansion and profitability

Evolus' Q4 2022 performance exceeded expectations, driven by strong revenue growth and customer acquisition.
The company's strategic focus on market share gains, international expansion, and profitability sets a positive trajectory.
Challenges from new competition and market dynamics require strategic responses to maintain leadership.
Opportunities in international expansion, corporate development, and market growth position Evolus for future success.

Evolus secures strategic partnership for growth in dermal filler market

Evolus' strong Q1 performance and strategic partnership with Symatese position the company for significant growth in the dermal filler market.
While facing challenges in safety comparisons and patient demographics, Evolus has opportunities to leverage its unique manufacturing process and upcoming data releases for market advantage.
Overall, Evolus is well-funded, poised for profitability, and focused on differentiating its product line for long-term success.

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

There are no frown lines from investors as the company is about to launch a competitor to Botox.

Why Evolus Stock Is Soaring 12% Higher Today

Evolus, Inc. (EOLS) CEO David Moatazedi on Q4 2018 Results - Earnings Call Transcript

News for Evolus Stock (EOLS)